ClinicalTrials.gg
CompletedNCT07251998Updated Nov 13, 2026

Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of ICP-332 Tablets and ICP-332 Tablets in Plaque Psoriasis, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Completed at 22 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2, Interventional, and Treatment

Updated Nov 13, 2026Now CompletedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 206 studies in Psoriasis with a site in China — 56 open to participants now, 66 under way, 22 of them phase 3. Psoriasis · China.

Enrollment
89th of 182
182 · median 171
Started
2025
with 35 others
Phase 2
42 of 206
11 open now
Registered
176th of 206
by date

Among the 206 studies in Psoriasis with a site in China, this one is the 89th largest by enrollment of the 182 interventional ones that give a count, is one of 36 that started in 2025, is one of 42 in phase 2, and was the 176th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

56 of the 206 studies in Psoriasis with a site in China are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Psoriasis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily participate in this study and have signed the Form (ICF).
  2. Male or female subjects aged ≥ 18 years and ≤ 70 years
  3. A history of plaque psoriasis for ≥6 months at baseline
  4. Meet the following three criteria:

    1. Psoriasis Area and Severity Index (PASI) score ≥12
    2. Static Physician's Global Assessment (sPGA) score ≥3
    3. Psoriasis affected Body Surface Area (BSA) ≥10%
  5. The subject requires systemic treatment and/or phototherapy.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed with non-plaque psoriasis.
  2. Subject had laboratory values meeting any of the protocol-specified criteria at Screening.
  3. Presence of clinically serious, progressive, or uncontrolled disease.
  4. Previous history of alcoholism or drug abuse (except for those who have been completely abstinent for more than 6 months before randomization).
  5. Pregnant or lactating women.
  6. The investigator accepts ICP-332 for any reason that the subject is not suitable for this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    ICP-332 Dose A

    Drug: ICP-332 Tablets

  • Experimental
    ICP-332 Dose B

    Drug: ICP-332 Tablets

  • Experimental
    ICP-332 Dose C

    Drug: ICP-332 Tablets

  • Placebo comparator
    ICP-332 Placebo

    Other: ICP-332 Placebo Tablets

Interventions

  • ICP-332 will be administered as tablet for 12 weeks

  • ICP-332 will be administered as tablet for 12 weeks

  • ICP-332 will be administered as tablet for 12 weeks

  • OtherICP-332 Placebo Tablets

    Placebo will be administered as tablet for 12 weeks

06

What researchers measure

Primary outcomes

  1. The Percentage of Participants With Moderate to Severe Psoriasis Experiencing a 75% Improvement (Reduction From Baseline) in PASI Score (PASI-75 Response Rate) at Week 12

    Time frame: Day 1 to Day 85

Secondary outcomes

  1. Percentage of Participants With PASI-50, PASI-75, PASI-90, PASI-100 on scheduled Visit(except W12 PASI 75)

    Time frame: Day 1 to Day 85

  2. Percentage of Participants at Week12 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate)

    Time frame: Day 1 to Day 85

  3. Number of Participants With Adverse Events

    Time frame: Day 1 to Day 113

  4. The peak concentration (Cmax)

    Time frame: Day 1, Day15, Day 29, Day 57

  5. The time to peak (Tmax)

    Time frame: Day 1, Day15, Day 29, Day 57

  6. The half-life (t1/2)

    Time frame: Day 1, Day15, Day 29, Day 57

  7. The area under the blood concentration-time curve (AUC0-∞ and AUC0-t)

    Time frame: Day 1, Day15, Day 29, Day 57

07

Study locations

22 sites
  • The Second Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241001, China
  • Beijing Tongren Hospital, Affiliated to Capital Medical University
    Beijing, Beijing Municipality 100005, China
  • Chongqing Traditional Chinese Medicine Hospital
    Chongqing, Chongqing Municipality 400011, China
  • Fujian Medical University First Affiliated Hospital
    Fuzhou, Fujian 350005, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510091, China
  • Shenzhen People's Hospital
    Shenzhen, Guangdong 518020, China
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 230601, China
  • The Second Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 450000, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 471000, China
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434020, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu 215002, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212001, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
  • Shandong Provincial Hospital of Dermatology
    Jinan, Shandong 250022, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Shanghai Dermatology Hospital
    Shanghai, Shanghai Municipality 200443, China
  • Chengdu Second People's Hospital
    Chengdu, Sichuan 610000, China
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin Municipality 300120, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650000, China
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang 310006, China
  • Hangzhou Third People's Hospital
    Hangzhou, Zhejiang 310009, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Oct 2026, 10 months.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 10 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

Completion moved once since we started tracking on Sep 25, 2026: May 2027 → Oct 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 26, 2025
StartActual
Dec 22, 2025
Primary completionActual
Oct 30, 2026
CompletionActual
Oct 30, 2026was May 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Sites
21 sites added
Show 21 added (21 China)
  • The Second Affiliated Hospital of Wannan Medical College · Wuhu, China
  • Beijing Tongren Hospital, Affiliated to Capital Medical University · Beijing, China
  • Chongqing Traditional Chinese Medicine Hospital · Chongqing, China
  • Fujian Medical University First Affiliated Hospital · Fuzhou, China
  • Dermatology Hospital of Southern Medical University · Guangzhou, China
  • Shenzhen People's Hospital · Shenzhen, China
  • The Second Hospital of Hebei Medical University · Shijiazhuang, China
  • The Second Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
  • Henan Provincial People's Hospital · Zhengzhou, China
  • Jingzhou Central Hospital · Jingzhou, China
  • Xiangya Hospital of Central South University · Changsha, China
  • Suzhou Municipal Hospital · Suzhou, China
  • Affiliated Hospital of Jiangsu University · Zhenjiang, China
  • Qilu Hospital of Shandong University · Jinan, China
  • Shandong Provincial Hospital of Dermatology · Jinan, China
  • Huashan Hospital Affiliated to Fudan University · Shanghai, China
  • Chengdu Second People's Hospital · Chengdu, China
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital · Tianjin, China
  • The First Affiliated Hospital of Kunming Medical University · Kunming, China
  • Hangzhou First People's Hospital · Hangzhou, China
  • Hangzhou Third People's Hospital · Hangzhou, China
Nov 13, 2026
Study completion
May 2027→Oct 30, 2026 (actual)
Nov 13, 2026
Enrollment
172 (estimated)→182 (actual)
Nov 13, 2026
Secondary outcomes
7 added
What changed in the outcomes
  • AddedPercentage of Participants With PASI-50, PASI-75, PASI-90, PASI-100 on scheduled Visit(except W12 PASI 75)Time frame: Day 1 to Day 85
  • AddedPercentage of Participants at Week12 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate)Time frame: Day 1 to Day 85
  • AddedNumber of Participants With Adverse EventsTime frame: Day 1 to Day 113
  • AddedThe peak concentration (Cmax)Time frame: Day 1, Day15, Day 29, Day 57
  • AddedThe time to peak (Tmax)Time frame: Day 1, Day15, Day 29, Day 57
  • AddedThe half-life (t1/2)Time frame: Day 1, Day15, Day 29, Day 57
  • AddedThe area under the blood concentration-time curve (AUC0-∞ and AUC0-t)Time frame: Day 1, Day15, Day 29, Day 57
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    21 sites added
    Show 21 added (21 China)
    • The Second Affiliated Hospital of Wannan Medical College · Wuhu, China
    • Beijing Tongren Hospital, Affiliated to Capital Medical University · Beijing, China
    • Chongqing Traditional Chinese Medicine Hospital · Chongqing, China
    • Fujian Medical University First Affiliated Hospital · Fuzhou, China
    • Dermatology Hospital of Southern Medical University · Guangzhou, China
    • Shenzhen People's Hospital · Shenzhen, China
    • The Second Hospital of Hebei Medical University · Shijiazhuang, China
    • The Second Affiliated Hospital of Henan University of Science and Technology · Luoyang, China
    • Henan Provincial People's Hospital · Zhengzhou, China
    • Jingzhou Central Hospital · Jingzhou, China
    • Xiangya Hospital of Central South University · Changsha, China
    • Suzhou Municipal Hospital · Suzhou, China
    • Affiliated Hospital of Jiangsu University · Zhenjiang, China
    • Qilu Hospital of Shandong University · Jinan, China
    • Shandong Provincial Hospital of Dermatology · Jinan, China
    • Huashan Hospital Affiliated to Fudan University · Shanghai, China
    • Chengdu Second People's Hospital · Chengdu, China
    • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital · Tianjin, China
    • The First Affiliated Hospital of Kunming Medical University · Kunming, China
    • Hangzhou First People's Hospital · Hangzhou, China
    • Hangzhou Third People's Hospital · Hangzhou, China
    Study completion May 2027→Oct 30, 2026 (now actual)
    Enrollment 172 (estimated)→182 (actual)
    Secondary outcomes 7 added
    What changed in the outcomes
    • AddedPercentage of Participants With PASI-50, PASI-75, PASI-90, PASI-100 on scheduled Visit(except W12 PASI 75)Time frame: Day 1 to Day 85
    • AddedPercentage of Participants at Week12 With sPGA Score of 0 or 1 (sPGA0/1 Response Rate)Time frame: Day 1 to Day 85
    • AddedNumber of Participants With Adverse EventsTime frame: Day 1 to Day 113
    • AddedThe peak concentration (Cmax)Time frame: Day 1, Day15, Day 29, Day 57
    • AddedThe time to peak (Tmax)Time frame: Day 1, Day15, Day 29, Day 57
    • AddedThe half-life (t1/2)Time frame: Day 1, Day15, Day 29, Day 57
    • AddedThe area under the blood concentration-time curve (AUC0-∞ and AUC0-t)Time frame: Day 1, Day15, Day 29, Day 57
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07251998
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Dec 22, 2025
Primary completion
Oct 30, 2026
Completion
Oct 30, 2026
Last update
Nov 13, 2026

Study contacts

Yuling Shi
principal investigator · Shanghai Dermatology Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ICP-332

Start the discussion